Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017, Article ID 2674502, 8 pages
https://doi.org/10.1155/2017/2674502
Research Article

PET Imaging of FSHR Expression in Tumors with 68Ga-Labeled FSH1 Peptide

1Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu 214063, China
2Department of Radiology, China-Japan Union Hospital of Jilin University, Changchun, Jilin 130033, China
3Nanjing Medical University, Nanjing, Jiangsu 210029, China
4Zhengzhou University, Zhengzhou, Henan 450001, China

Correspondence should be addressed to Min Yang; gro.mnisj@nimgnay

Received 29 March 2017; Revised 7 July 2017; Accepted 25 July 2017; Published 23 August 2017

Academic Editor: Shengxian Rao

Copyright © 2017 Donghui Pan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

FSHR is an appealing target for cancer theranostics. Radiolabeled FSH1 and its derivatives have shown potential to in vivo detect FSHR expression. However, moderate labeling yields (~50% nondecay-corrected) may partially limit their wide use. 68Ga is an excellent PET nuclide due to availability, nearly quantitative reaction, and short physical half-life. In this study, 68Ga labeled FSH1 peptide was developed for imaging of FSHR in cancers. In vitro studies and MicroPET imaging were performed in PC-3 prostate tumor model. [68Ga] Ga-NOTA-MAL-FSH1 can be produced within 20 min with yield and the radiochemical purity was greater than 95%. It showed that [68Ga] Ga-NOTA-MAL-FSH1 possessed FSHR binding affinities. The tracer was stable in PBS and human serum for at least 2 hours. MicroPET imaging revealed that the PC-3 xenografts were clearly visualized and the tumor uptakes were , , and % ID/g at 0.5, 1 h, and 2 h postinjection. The corresponding tumor to blood and tumor to muscle ratios were , , and and , , and , respectively. FSHR binding specificity was also demonstrated by reduced tumor uptake of [68Ga] Ga-NOTA-MAL-FSH1 after coinjecting excess unlabeled FSH1 peptide. The favorable characters of [68Ga] Ga-NOTA-MAL-FSH1 such as convenient synthesis and specific tumor uptake warrant its further investigation for FSHR expression imaging.

1. Introduction

Follicle-stimulating hormone (FSH) is a central hormone in mammalian reproductive biology. It promotes the mature spermatogenesis for men and follicular maturation for women, respectively. FSH receptor (FSHR) is a glycosylated transmembrane protein belonging to the family of G-protein-coupled receptors. In adult humans and animals, low levels of FSHR were expressed only in endothelial cells of ovary and testis [14].

Immunostaining showed that FSHR was overexpressed in the vasculatures of various solid tumors including prostate, breast, lung, and ovarian cancer. On the contrary, healthy and nonmalignant inflammatory tissues were always FSHR negative [5]. These findings imply that the receptor may be a target for cancer detection and image guided cancer surgery. Moreover, the expression level of FSHR correlates strongly with the response of tumors to antiangiogenic therapies. One clinical study in patients found that the FSHR levels in the primary tumors correlated well with the response to antiangiogenic tyrosine kinase inhibitors (sunitinib) [6]. The percentage of FSHR stained vessels of the responsive patients (~60%) was significantly higher than those in the stable or nonresponsive group (~10% and ~7%, resp.). These characteristics render FSHR an attractive choice for tumor theranostics. Using the FSHR-targeting strategy, paclitaxel attached to FSH peptide was loaded into nanoparticles and the compound displayed antitumor effects [7]. Meanwhile, a nanographene oxide conjugated to a monoclonal antibody against FSHR was successfully developed for targeting delivery of therapeutics [8].

Besides therapy, noninvasive imaging of FSHR is of benefit to monitor biochemical changes and target abundance within a testing subject. Radiolabeled peptides toward receptors have attracted considerable interest for cancer imaging due to fast clearance, high specificity, excellent tissue penetration, and low immunogenicity [913]. Preliminary studies revealed that 18FAl labeled FSH1 and its derivatives (FSH2) possessed FSHR binding specificity and might be potential probes to in vivo detect FSHR expression [13, 14]. However, moderate labeling yields (~50% nondecay-corrected) may partially limit their wide use.

Compared with 18F, a metallic positron emitter, 68Ga, can be conveniently obtained from an in-house 68Ge/68Ga generator and independent of an onsite cyclotron. With a half-life of 68 min, it is also suitable for the pharmacokinetics of many peptides. In addition, biomolecules can be labeled with 68Ga by nearly quantitative reaction with macrocyclic chelators. It allows possible kit formulation and accelerated the application of the probes [15].

Previous studies showed that the uptake of 18FAl labeled FSH1 in FSHR positive PC-3 xenograft was significantly higher than those of FSH2 counterpart at 1 h postinjection ( ID/g versus  ID/g, resp.). FSH1 peptide may be more suitable for tumor imaging than FSH2 [13, 14]. In this study, FSH1 conjugated to maleimide-NOTA, NOTA-MAL-FSH1, was labeled with 68Ga (Figure 1). The in vitro affinity and the in vivo tumor targeting properties of [68Ga] Ga-NOTA-MAL-FSH1 were also determined in PC-3 tumor models.

Figure 1: Schemes for radiosynthesis of [68Ga] Ga-NOTA-MAL-FSH1.

2. Materials and Methods

All commercial reagents were of analytical grade. FSH1 peptide was custom made by Apeptide Co., Ltd., (Shanghai, China). NOTA-MAL-FSH1 was synthesized according to the literature and the purity was greater than 95% [13].

The conditions for HPLC system are as follows [16]: A Waters high-performance liquid chromatography (HPLC) system with a Waters 2998 photodiode array detector (PDA) and a preparative C18 HPLC column (5 μm, 250 × 10 mm, Phenomenex) was used for peptide conjugated purification. The flow is 5 ml/min, and the mobile phase changed from 95% solvent (0.1% trifluoroacetic acid in water) and 5% solvent (0.1% trifluoroacetic acid in acetonitrile) (0–2 min) to 35% solvent and 65% solvent at 35 min. The UV absorbance was monitored at 218 nm.

The purities of compounds were analyzed by RP-HPLC on a Waters Breeze system equipped with a Radiomatic 610TR flow scintillation analyzer (PerkinElmer) and a Waters 2487 dual λ absorbance detector. A Luna C18 column (5 μm, 250 × 4.6 mm, Phenomenex) was used at a flow rate of 1 ml/min with the following buffer system: buffer , 0.1% v/v trifluoroacetic acid in water; buffer , 0.1% v/v trifluoroacetic acid (TFA) in acetonitrile (ACN); and a gradient of 95% buffer at 0–2 min to 35% buffer at 35 min.

The HPLC chromatogram and MS spectrum of NOTA-MAL-FSH1 were listed in Figure 2. MS measured 2968.5 for [M + H]+ (C133H210N36O39S, calculated molecular weight, 2968.1) [13]; [68Ga] GaCl3 was eluted from a 68Ge/68Ga-generator (ITG, Germany) with 0.05 M HCl. The PC-3 human prostate cancer cell line was purchased from Cell Bank of Shanghai Institutes for Biological Sciences.

Figure 2: HPLC chromatogram (a) and MS spectrum (b) of NOTA-MAL-FSH1.
2.1. Preparation of  68Ga-NOTA-MAL-FSH1

The fresh [68Ga] GaCl3 (185 MBq) was added to 300 μL 1 M HEPES buffer and followed 20 μg of NOTA-MAL-FSH1 (6.7 nmol) in 10 μL 0.2 M sodium acetate buffer (pH = 4). The mixture was incubated at 100°C for 10 min. After being diluted with 10 mL of deionized water, the complex was loaded into a Varian BOND ELUT C18 column. The labeled peptide was eluted with 200 μL 10 mM HCl in ethanol. The product was reconstituted in 3 ml saline and passed through a 0.22 μm Millipore filter into a sterile vial. Radiochemical purity was checked with the HPLC system. The retention time for 68Ga-NOTA-MAL-FSH1 was 14.2 min (Figure 3(a)).

Figure 3: HPLC radiochromatogram for (a) purified [68Ga] Ga-NOTA-MAL-FSH1 and (b) [68Ga] Ga-NOTA-MAL-FSH1 after 2 h incubation in PBS and (c) [68Ga] Ga-NOTA-MAL-FSH1 after 2 h incubation in human serum.
2.2. Octanol/PBS Partition Coefficient

To an Eppendorf tube filled with 0.5 mL of the radiolabeled peptide (10 μL, 370 KBq) in phosphate-buffered saline (pH 7.4), 0.5 mL of octanol was added. After stirring for 2 min at room temperature, the two layers were separated by centrifugation. Radioactivity in 100 μL of each layer was measured in a γ-counter (Perkin-Elmer), and log  values were calculated [17]. Experiments were performed in triplicate.

2.3. Stability Studies

10 μL 370 KBq [68Ga] Ga-NOTA-MAL-FSH1 in saline was incubated in 200 μL PBS or 200 μL human serum for 30, 60, and 120 min at 37°C, respectively. The stability of the labeled peptide in PBS was determined by directly injecting an aliquot of the solution into the HPLC at the preselected time points.

The serum was first mixed with 200 μL acetonitrile to precipitate the proteins. Subsequently, after centrifugation, supernatant was collected and analyzed by radio-HPLC [18]. Protein-binding fraction was calculated by dividing the radioactivity of the precipitation layer by the total activity used.

2.4. Cell Lines and Animal Models

PC-3 cells were cultured and grown in F-12 nutrient (Thermo Fisher) mixture supplemented with 10% (v/v) fetal bovine serum at 37°C in an atmosphere containing 5% CO2.

The PC-3 tumor model was generated by subcutaneous injection of 5 × 106 cells into the right front flank of male athymic nude mice (4 weeks old, SLAC Laboratory Animal Co., Ltd., China).

The mice were used for MicroPET studies when the tumor volume reached 100–300 mm3, which took about 2 weeks. The animal experiments were conducted in compliance with the national regulations and approved by local animal welfare committee.

2.5. Competitive Cell-Binding Assay

To obtain a homogenous mixture, equivalent of GaCl3 was added to [68Ga] Ga-NOTA-MAL-FSH1 and the final solution incubated again for 10 min. Binding affinities toward the FSHR for [68Ga] Ga-NOTA-MAL-FSH1 were determined in a competitive binding assay on PC-3 tumor cells using FSH1 as a receptor ligand [19]. PC-3 cells in 6-well plates (2 × 105 cells per well) were cultured until confluency. On the day of assay, cells were washed with binding buffer (RPMI, 0.5% bovine serum albumin). A range of 1 to 5000 nM FSH1 in binding buffer and 370 KBq [Ga] Ga-NOTA-MAL-FSH1 were added to each well. After incubating at 37°C for 2 h, medium was removed. Then, cells were washed with binding buffer and extracted from the wells by 0.1 M NaOH. Cell-associated radioactivity was determined in a γ-counter (PerkinElmer). Experiments were performed in triplicate. Inhibitory concentration of 50% (IC50) values was determined by GraphPad Prism software (version 5.0).

2.6. Cell Uptakes

PC-3 cells were suspended in 500 μL RPMI 1640 and seeded in 24-well tissues culture plates (1 × 105 cells per well) for overnight incubation. After washing with PBS, the cells were incubated with 370 KBq [68Ga] Ga-NOTA-MAL-FSH1 in the presence or absence of unlabeled FSH1 (to a final concentration of 1 μM) at 37°C for 15, 30, 60, and 120 min, respectively. The cells were washed 3 times with ice-cold PBS and lysed in 0.5 mL of 1.0 M NaOH. The remaining radioactivity was measured in the γ-counter. Cell uptakes were expressed as the percentage of added radioactive dose (% AD). Experiments were performed in triplicate.

2.7. MicroPET Imaging

Mice was injected intravenously with 100 μL 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 in saline under isoflurane anesthesia and subjected to MicroPET imaging. The breathing and body temperature of the mice were monitored by BioVet CT1 system (M2M Imaging Corp.). For the blocking experiment, unlabeled peptide (10 mg/kg body weight) and 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 were coinjected into five mice. Static PET images were acquired for 5 min using an Inveon MicroPET/CT scanner (Siemens Medical Solutions) at 30 min, 1 h, and 2 h postinjection. The quantification analysis of PET images was performed using the same method as previously reported [13].

2.8. Biodistribution Studies

A number of twenty tumor bearing mice were euthanized with isoflurane (inhalation excess) and dissected at 0.5 h, 1 h, and 2 h (5 mice per time-point) after administrating 740 KBq [68Ga] Ga-NOTA-MAL-FSH1. To determine the specific uptake, mice were coinjected with the probe with 100 μg of unmodified peptide and sacrificed at 1 h p.i. Normal organs and tumors were collected and weighed. The radioactivity was measured by the γ-counter and the percentage of injected dose per gram of tissue (% ID/g) was determined.

2.9. Statistical Analysis

Statistical analyses were performed using GraphPad Prism (version 5.0). Data were analyzed using the unpaired, 2-tailed Student’s -test. Differences at the 95% confidence level () were considered to be statistically significant.

3. Results

3.1. Chemistry and Radiochemistry

The labeling was performed within 20 min, with a decay-corrected yield of () and a radiochemical purity of more than 95%. The specific activity was determined to be at least 25 GBq/μmol.

3.2. In Vitro Characterization

The in vitro stability of the 68Ga labeled tracer was evaluated by incubating in PBS or human serum at 37°C, respectively. Protein-binding fraction was determined to be . The probe displayed high in vitro stability and showed no degradation products or release of 68Ga whether in PBS or human serum (Figures 3(b) and 3(c)). The radiochemical purities of [68Ga] Ga-NOTA-MAL-FSH1 were greater than 95% after 2 h in vitro incubation (Table 1).

Table 1: Radiochemical purity (%) of [68Ga] Ga-NOTA-MAL-FSH1 after 0.5, 1, and 2 h incubation in PBS and human serum, respectively.

The partition coefficient (log ) of [68Ga] Ga-NOTA-MAL-FSH1 was determined to be .

3.3. Cell-Binding Assay

The binding of [Ga] Ga-NOTA-MAL-FSH1 to the FSHR on PC-3 tumors was inhibited by various concentrations of nonlabeled FSH1, and the IC50 values were  nM (Figure 4).

Figure 4: Cell uptake assays of [68Ga] Ga-NOTA-MAL-FSH1 in PC-3 cells.
3.4. Cell Uptake

As shown in Figure 5, [68Ga] Ga-NOTA-MAL-FSH1 uptakes in PC-3 cells were , , , and % AD for incubating at 15, 30, 60, and 120 min at 37°C, respectively. In the presence of blocking agent, the cell uptakes were significantly reduced to AD after incubating at 60 min, indicating the receptor targeting specificity of the probe.

Figure 5: Competition of specific bindings of [68Ga] Ga-NOTA-MAL-FSH1 with FSH1.
3.5. MicroPET Imaging

Representative coronal MicroPET images of PC-3 tumor bearing mice ( per group) at different times after intravenous injection of 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 are shown in Figure 6. PC-3 xenografts were visible with high tumor-to-background contrast. The tumor uptake of [68Ga] Ga-NOTA-MAL-FSH1 was determined to be , , and % ID/g at 30, 60, and 120 min (Table 2).

Table 2: Radioactivity accumulation (data obtained from MicroPET) in selected organs of PC-3 tumor bearing nude mice after injection of [68Ga] Ga-NOTA-MAL-FSH1 at different time points (/group, mean ± SD).
Figure 6: In vivo PET imaging of PC-3 xenografted mice with [68Ga] Ga-NOTA-MAL-FSH1. Decay-corrected whole-body coronal MicroPET images of PC-3 tumor bearing mice at 30, 60, and 120 min after injection of 3.7 MBq [68Ga] Ga-NOTA-MAL-FSH1 without (a) and with (c) blocking dose. Tumors are indicated by arrows. Quantification of [68Ga] Ga-NOTA-MAL-FSH1 in PC-3 tumor, liver, kidneys, and muscle without (b) and with (d) blocking dose. ROIs are shown as mean % ID/g ± SD.

High activity accumulation was also observed in the kidney ( ID/g at 1 h p.i.) which indicated that 68Ga labeled peptide was mainly cleared via the urinary system. The in vivo FSHR binding property of [68Ga] Ga-NOTA-MAL-FSH1 was also confirmed by blocking studies. Injection of a large excess of unlabeled FSH1 decreased PC-3 tumor uptakes to  ID/g at 1 h postinjection.

3.6. Biodistribution Studies

The results of the biodistribution studies are summarized in Table 3. The tumor uptake of [68Ga] Ga-NOTA-MAL-FSH1 was significantly higher than those in the blood and normal organs such as heart, liver, spleen, bone, muscle, and testis at 0.5 h, 1 h, and 2 h postinjection (). Due to longer retention of the tracer in tumor, the tumor to blood and tumor to muscle uptake ratios were , , and and , , and , respectively.

Table 3: Biodistribution of [68Ga] Ga-NOTA-MAL-FSH1 in PC-3 tumor bearing mice at various times after injection ().

Coinjection of excess FSH1 along with [68Ga] Ga-NOTA-MAL-FSH1 resulted in significantly reduced radioactivity accumulation in tumor from ID/g to ID/g at 1 h postinjection.

4. Discussion

The recent introduction of 68Ga PET imaging into clinical practice represents a landmark in the ongoing developments in functional and metabolic imaging that is independent of the availability of a cyclotron [20]. Site-specific labeling is important as it provides chemically uniform radioconjugates with well-defined in vivo properties. Maleimide-NOTA is a NOTA-derivatized chelating system, which has specific reactivity toward thiol group [20]. In this study, NOTA-MAL was conjugated to the cysteine residue of FSH1 for site-specific labeling.

Previous studies have documented the overexpression of FSHR in human prostate cancer tissues, particularly in relation to hormone-resistant prostate tumors [9]. Human prostate cancer PC-3 is a hormone-resistant prostate tumor. Thus the characteristics of [68Ga] Ga-NOTA-MAL-FSH1 were preliminary investigated in a PC-3 tumor model.

[68Ga] Ga-NOTA-MAL-FSH1 could be achieved in about 20 min through solid-phase extraction with satisfactory radiochemical purity. Our previous studies showed that the radiolabeling yields of 18FAl labeled FSH1 and its derivatives, FSH2, were % and (nondecay-corrected), respectively, after 30 min preparation. After decay-corrected determination, the labeling yield of 18FAl labeled FSH1 and its derivatives was and , respectively. Compared with them, the decay-corrected labeling yield (~90%) of 68Ga-NOTA-MAL-FSH1 was significantly higher than those of 18FAl labeled counterpart [13, 14].

The radiolabeled NOTA-MAL-FSH1 was hydrophilic as indicated by the negative partition coefficients, which is similar to those of 18FAl labeled FSH1 ( versus , resp.). [68Ga] Ga-NOTA-MAL-FSH1 showed in vitro stability in human serum and PBS for at least 2 hours.

The IC50 values of displacement [68Ga] Ga-NOTA-MAL-FSH1 with FSHR antagonist, FSH1, were similar to 18FAl labeled counterparts, which primarily indicated the affinity of the tracer for FSHR was retained (123 nM versus 252 nM, resp.). In vitro cell uptake assays also showed that coincubation with excess unlabeled FSH1 significantly blocked tumor uptake demonstrating the receptor binding specificity of the PET probe.

After labeling with 68Ga, we first performed MicroPET scans for [68Ga] Ga-NOTA-MAL-FSH1 in the PC-3 prostate tumor xenograft model. The tracer showed prominent uptakes in the tumor compared with normal tissues such as heart, brain muscle, and livers except kidneys. It was also noted that the uptake values in PC-3 xenografts were slightly lower than those of 18FAl labeled FSH1 ( ID/g versus ID/g at 60 min p.i., resp., ) [13]. The detailed mechanism was under investigation.

The results of the biodistribution study were consistent with the findings of PET imaging. It showed clear reduction of the radioactivity in the normal organs. The muscle uptakes of the probe were slightly lower than those of 18FAl-NOTA-MAL-FSH1 ( versus % ID/g at 1 h p.i., resp.). The resulting tumor to muscle uptake ratio of the probe was more favorable than those of 18FAl labeled FSH1 peptides ( versus at 1 h p.i., resp.) [13]. It indicated that 68Ga labeled agent might be an alternative to 18FAl labeled compounds for PET imaging of FSHR expression where a cyclotron is of limited to access.

The FSHR specificity of [68Ga] Ga-NOTA-MAL-FSH1 was also confirmed by effective tumor uptake inhibition in the presence of excess FSH1 in both noninvasive PET imaging and biodistribution studies. The blocking study suggested that the tumor uptake of the tracer was specific to FSHR.

5. Conclusion

In summary, we have successfully developed a radiolabeled tracer, [68Ga] Ga-NOTA-MAL-FSH1 with high yield and purity. Preclinical data indicates that [68Ga] Ga-NOTA-MAL-FSH1 is promising for noninvasive visualization of FSHR expression in vivo. Further investigation of this novel radiotracer for detection of other FSHR tumor models such as breast and ovarian cancers is currently underway.

Conflicts of Interest

The authors declare no competing financial interests.

Authors’ Contributions

Guifeng Liu equally contributed to the work.

Acknowledgments

This work was partially supported by National Natural Science Foundation (81401450, 51473071, 81472749, 21504034, 21401084, and 31671035), Jiangsu Province Science and Technology Foundation (BE2014609, BE2016632, and BK20170204), and Jiangsu Provincial Medical Innovation Team (H201529 and Q201406).

References

  1. N. S. MacKlon and B. C. J. M. Fauser, “Follicle development during the normal menstrual cycle,” Maturitas, vol. 30, no. 2, pp. 181–188, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Simoni, J. Gromoll, and E. Nieschlag, “The follicle-stimulating hormone receptor: biochemistry, molecular biology, physiology, and pathophysiology,” Endocrine Reviews, vol. 18, no. 6, pp. 739–773, 1997. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Vannier, H. Loosfelt, G. Meduri, C. Pichon, and E. Milgrom, “Anti-human FSH receptor monoclonal antibodies: Immunochemical and immunocytochemical characterization of the receptor,” Biochemistry, vol. 35, no. 5, pp. 1358–1366, 1996. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Papadimitriou, P. Kountourakis, A. E. Kottorou et al., “Follicle-Stimulating Hormone Receptor (FSHR): A Promising Tool in Oncology?” Molecular Diagnosis and Therapy, vol. 20, no. 6, pp. 523–530, 2016. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Radu, C. Pichon, P. Camparo et al., “Expression of follicle-stimulating hormone receptor in tumor blood vessels,” The New England Journal of Medicine, vol. 363, no. 17, pp. 1621–1630, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Siraj, C. Pichon, A. Radu, and N. Ghinea, “Endothelial follicle stimulating hormone receptor in primary kidney cancer correlates with subsequent response to sunitinib,” Journal of Cellular and Molecular Medicine, vol. 16, no. 9, pp. 2010–2016, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. C. W. Lee, L. Guo, D. Matei, and K. Stantz, “Development of follicle-stimulating hormone receptor binding probes to image ovarian xenografts,” Journal of Biotechnology & Biomaterials, vol. 05, no. 03, 2015. View at Publisher · View at Google Scholar
  8. D. Yang, L. Feng, C. A. Dougherty et al., “In vivo targeting of metastatic breast cancer via tumor vasculature-specific nano-graphene oxide,” Biomaterials, vol. 104, pp. 361–371, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Hong, Y. Yan, S. Shi et al., “PET of follicle-stimulating hormone receptor: Broad applicability to cancer imaging,” Molecular Pharmaceutics, vol. 12, no. 2, pp. 403–410, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. C. D. A. Ferreira, L. L. Fuscaldi, D. M. Townsend, D. Rubello, and A. L. B. D. Barros, “Radiolabeled bombesin derivatives for preclinical oncological imaging,” Biomedicine and Pharmacotherapy, vol. 87, pp. 58–72, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. J. Shi, F. Wang, and S. Liu, “Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging,” Biophysics Reports, vol. 2, no. 1, pp. 1–20, 2016. View at Publisher · View at Google Scholar
  12. X. Sun, Y. Li, T. Liu, Z. Li, X. Zhang, and X. Chen, “Peptide-based imaging agents for cancer detection,” Advanced Drug Delivery Reviews, 2016. View at Publisher · View at Google Scholar
  13. L. Bodei, D. J. Kwekkeboom, M. Kidd, I. M. Modlin, and E. P. Krenning, “Radiolabeled Somatostatin Analogue Therapy Of Gastroenteropancreatic Cancer,” Seminars in Nuclear Medicine, vol. 46, no. 3, pp. 225–238, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Xu, D. Pan, C. Zhu et al., “Pilot study of a novel 18F-labeled FSHR probe for tumor imaging,” Molecular Imaging and Biology, vol. 16, no. 4, pp. 578–585, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Zhu, Q. Xu, D. Pan et al., “Prostate cancer imaging of FSHR antagonist modified with a hydrophilic linker,” Contrast Media and Molecular Imaging, vol. 11, no. 2, pp. 99–105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Lang, W. Li, N. Guo et al., “Comparison study of [18F]FAl-NOTA-PRGD2, [18F] FPPRGD2, and [68Ga]Ga-NOTA-PRGD2 for PET imaging of U87MG tumors in mice,” Bioconjugate Chemistry, vol. 22, no. 12, pp. 2415–2422, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. I. Dijkgraaf, G. M. Franssen, W. J. McBride et al., “PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog,” Journal of Nuclear Medicine, vol. 53, no. 6, pp. 947–952, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. D. O. Kiesewetter, N. Guo, J. Guo et al., “Evaluation of an [18F]AlF-NOTA analog of exendin-4 for imaging of GLP-1 receptor in insulinoma,” Theranostics, vol. 2, no. 10, pp. 999–1009, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. G. Kramer-Marek, D. O. Kiesewetter, L. Martiniova, E. Jagoda, S. B. Lee, and J. Capala, “[18F]FBEM-ZHER2:342-Affibody molecule - A new molecular tracer for in vivo monitoring of HER2 expression by positron emission tomography,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 1008–1018, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. E. W. Price and C. Orvig, “Matching chelators to radiometals for radiopharmaceuticals,” Chemical Society Reviews, vol. 43, no. 1, pp. 260–290, 2014. View at Publisher · View at Google Scholar · View at Scopus